MK
Therapeutic Areas
Carisma Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CT-0508 | HER2-overexpressing solid tumors | Phase 1 |
| CT-0508 + Pembrolizumab | HER2-overexpressing solid tumors | Phase 1 |
| CT-0525 | HER2-overexpressing solid tumors (allogeneic) | Pre-clinical |
| CT-1119 | Mesothelin-expressing solid tumors | Pre-clinical |
Leadership Team at Carisma Therapeutics
SK
Steven Kelly
President and Chief Executive Officer
EP
Eugene P. Kennedy
Chief Medical Officer
JH
John H. Lee
Senior Vice President, Early Clinical Development
DB
Deborah Baron
Chief Financial and Corporate Strategy Officer
SM
Sylvia McBrinn
Chief Operating Officer
SG
Saar Gill
Co-Founder and Scientific Advisor
MM
Michael Milone
Co-Founder and Scientific Advisor
JT
John T. Curnutte
Chairman of the Board of Directors